Orca Bio's Precision Cell Therapy Orca-T Shows Striking Survival Rates, Nears Pivotal FDA Decision

MENLO PARK, CA – February 05, 2026 – By Daniel Howard

Orca Bio, a late-stage biotechnology firm, has unveiled compelling new data reinforcing the promise of its high-precision cell therapy, Orca-T, as a potentially transformative treatment for patients with aggressive blood cancers. The findings, presented at the 2026 Tandem Meetings of ASTCT® and CIBMTR®, highlight significantly improved survival rates and a dramatic reduction in life-threatening complications compared to standard treatments, positioning the therapy for a landmark FDA decision expected later this year.

For decades, allogeneic hematopoietic stem cell transplantation (alloHSCT) has been a curative option for hematological malignancies like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), but its success is often marred by severe side effects, most notably graft-versus-host disease (GVHD). Orca Bio's approach with Orca-T—a precisely formulated infusion of purified stem and immune cells—is designed to overcome this challenge. The latest data suggests the company is making significant strides, not only in clinical efficacy but also in the complex logistics required to deliver such a therapy at scale.

Redefining Transplant Outcomes with Precision

The new analyses presented provide a clearer picture of Orca-T's potential, particularly in older and more vulnerable patient populations. One key analysis focused on patients aged 60-75 undergoing reduced intensity conditioning (RIC), a less toxic chemotherapy regimen. Compared to a historical cohort from the CIBMTR registry who received the current standard of care with post-transplant cyclophosphamide (PTCy), patients treated with Orca-T demonstrated markedly better outcomes.

At two years post-transplant, overall survival for the Orca-T group was 84%, compared to just 61% for the PTCy group. Relapse-free survival was similarly impressive at 79% versus 53%. Perhaps most critically, the rate of graft-versus-host-disease relapse-free survival (GRFS)—a key metric measuring survival without major complications—was 72% for Orca-T patients, a stark contrast to 45% in the PTCy cohort.

“Patients undergoing reduced intensity conditioning allogeneic stem cell transplantation often face a tradeoff between tolerability and long-term disease control,” said Caspian Oliai, MD, a primary investigator on the SERENE-T Phase 2 study. “The clinical evidence being generated today, which suggests Orca-T may improve key outcomes by reducing GVHD without increasing infection risk or relapse rate, provides a strong foundation for our ongoing evaluation of Orca-T in this setting.”

The therapy's impact on GVHD was profound. At one year, the rate of severe acute GVHD was 0% with Orca-T, compared to 6% with PTCy. This reduction in complications is central to Orca-T's value proposition. Independent experts note that while comparisons to historical cohorts require careful interpretation, the magnitude of the difference in GRFS is clinically meaningful. One hematologist not affiliated with the studies commented that Orca-T appears to be “meaningfully shifting the risk-benefit balance in transplant,” delivering improved survival with significantly less toxicity.

Further analyses focusing on patients with MDS underscored these benefits. In a post-hoc analysis, MDS patients treated with Orca-T showed a remarkable 100% overall survival at one, two, and three years, while survival in the PTCy cohort declined from 80% to 62% over the same period. Non-relapse mortality at one year was 0% for Orca-T versus 9.9% for PTCy, highlighting a substantial safety advantage.

From Clinical Success to Commercial Reality

With a Biologics License Application (BLA) already under Priority Review by the U.S. Food and Drug Administration, Orca Bio is rapidly transitioning from a research-focused entity to a potential commercial powerhouse. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of April 6, 2026, making a regulatory decision imminent. The therapy has already received Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug designations, underscoring its potential to address a significant unmet need.

Anticipating a favorable outcome, Orca Bio has focused intensely on a critical hurdle for all cell therapies: manufacturing and distribution. The company presented an analysis of 243 clinical cell therapies produced and shipped between 2019 and 2024. The results were a logistical tour de force: 100% of products were delivered to transplant centers across the U.S. within 70 hours, and 99% were infused into patients within the 72-hour viability window. This reliability is crucial for a therapy that involves living cells and a tightly coordinated process between a manufacturing site and a patient's bedside.

“These data continue to reinforce the strength of Orca-T across both clinical outcomes and operational execution,” said Nate Fernhoff, Ph.D., co-founder and chief executive officer at Orca Bio. “The consistency of these results, along with our ability to reliably manufacture and deliver Orca-T across the U.S., highlights the potential of this therapy to make a meaningful difference for patients with hematologic malignancies.”

To meet projected commercial demand, the company has already opened a large-scale manufacturing facility in Sacramento, California, capable of producing thousands of therapies annually, and is establishing an East Coast presence to further strengthen its supply chain.

Expanding Access with a Next-Generation Therapy

While Orca-T is poised to make its mark, Orca Bio is already looking to the future with Orca-Q, its second-generation investigational therapy. Orca-Q is designed to address one of the most significant limitations in transplantation: the need for a perfectly matched donor. This new therapy is being developed for patients who only have a haploidentical, or half-matched, donor, a group that comprises a large portion of those in need of a transplant.

Early data from a Phase 1 study of Orca-Q is encouraging. In 39 patients with various blood cancers, the therapy led to successful engraftment in all patients. Three-year overall survival was a promising 77%, with very low rates of severe GVHD. In a specific patient subgroup receiving a particular conditioning regimen, outcomes were even better, with 85% survival and 0% incidence of severe acute or chronic GVHD.

By developing Orca-Q, the company is strategically planning to broaden its impact, potentially making high-precision cell therapy an option for a much larger patient population. This forward-looking pipeline, combined with the imminent potential approval of Orca-T, signals a clear ambition to not just enter the market, but to fundamentally redefine the standards of care in allogeneic cell therapy.